Capstone Investment Advisors
JANX icon

Capstone Investment Advisors’s Janux Therapeutics JANX Stock Holding History

Capstone Investment Advisors’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,508
Closed -$269K – 1729
2025
Q4 		$269K Buy
+19,508
New +$459K ﹤0.01% 1405
2024
Q2 		– Sell
-52,300
Closed -$1.97M – 2273
2024
Q1 		$1.97M Buy
+52,300
New +$1.14M 0.01% 789

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capstone Investment Advisors's JANX Position: Q1 2026 in Review

Capstone Investment Advisors sold out of Janux Therapeutics (JANX) in Q1 2026, closing a stake of 19,508 shares — an estimated $269K sold.

Capstone Investment Advisors first reported a position in JANX in Q1 2024 and held it in 2 quarters. The position peaked at $1.97M in Q1 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Capstone Investment Advisors reported no remaining Janux Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Capstone Investment Advisors sold 19,508 Janux Therapeutics shares in Q1 2026, an estimated $269K.
  • Capstone Investment Advisors first reported a position in Janux Therapeutics in Q1 2024 and held it in 2 quarters.
  • Capstone Investment Advisors's Janux Therapeutics position peaked at $1.97M in Q1 2024.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.